Which has better earnings and valuation, DOCS or COA?

Coats Group has higher revenue and earnings than Dr. Martens. Coats Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Martens £764.90M 0.80 £68.97M £2.40 26.79 Coats Group £1.60B 0.92 £75.12M £5.39 14.30

Is DOCS or COA more profitable?

Coats Group has a net margin of 6.60% compared to Dr. Martens' net margin of 3.11%. Coats Group's return on equity of 14.43% beat Dr. Martens' return on equity. Company Net Margins Return on Equity Return on Assets Dr. Martens 3.11% 6.89% 8.12% Coats Group 6.60% 14.43% 8.48%

Do analysts prefer DOCS or MUL?

Dr. Martens currently has a consensus target price of GBX 105, suggesting a potential upside of 63.29%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Martens is more favorable than Mulberry Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Martens 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Mulberry Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, DOCS or MUL?

Dr. Martens has higher revenue and earnings than Mulberry Group. Mulberry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Martens £764.90M 0.80 £68.97M £2.40 26.79 Mulberry Group £125.47M 1.52 -£39.32M -£13.00 N/A

Do analysts prefer DOCS or PTD?

Dr. Martens presently has a consensus target price of GBX 105, suggesting a potential upside of 63.29%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Martens is more favorable than Pittards. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Martens 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Pittards 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, DOCS or PTD?

Dr. Martens has higher revenue and earnings than Pittards. Pittards is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Martens £764.90M 0.80 £68.97M £2.40 26.79 Pittards £20.37M 0.00 N/A £0.03 N/A

Is DOCS or PTD more profitable?

Dr. Martens has a net margin of 3.11% compared to Pittards' net margin of 1.97%. Dr. Martens' return on equity of 6.89% beat Pittards' return on equity. Company Net Margins Return on Equity Return on Assets Dr. Martens 3.11% 6.89% 8.12% Pittards 1.97% 3.08% 2.32%

Do analysts prefer DOCS or NBU?

Dr. Martens presently has a consensus price target of GBX 105, suggesting a potential upside of 63.29%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts plainly believe Dr. Martens is more favorable than Naibu Global International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Martens 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Naibu Global International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, DOCS or NBU?

Dr. Martens has higher revenue and earnings than Naibu Global International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Martens £764.90M 0.80 £68.97M £2.40 26.79 Naibu Global International N/A N/A N/A N/A N/A

Dr. Martens (DOCS) Competitors

GBX 64.30 -0.90 (-1.37%)

As of 09/11/2026 12:15 PM Eastern

Compare

DOCS vs. WOSG, COA, MUL, PTD, and NBU

Should you buy Dr. Martens stock or one of its competitors? Dr. Martens's main competitors and comparable companies include Watches of Switzerland Group (WOSG), Coats Group (COA), Mulberry Group (MUL), Pittards (PTD), and Naibu Global International (NBU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "textiles, apparel & luxury goods" industry.

How does Dr. Martens compare to Watches of Switzerland Group?

Watches of Switzerland Group (LON:WOSG) and Dr. Martens (LON:DOCS) are both small-cap consumer discretionary companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

53.9% of Watches of Switzerland Group shares are owned by institutional investors. Comparatively, 32.2% of Dr. Martens shares are owned by institutional investors. 4.4% of Watches of Switzerland Group shares are owned by insiders. Comparatively, 2.9% of Dr. Martens shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Watches of Switzerland Group had 1 more articles in the media than Dr. Martens. MarketBeat recorded 1 mentions for Watches of Switzerland Group and 0 mentions for Dr. Martens. Watches of Switzerland Group's average media sentiment score of 0.00 equaled Dr. Martens'average media sentiment score.

Company	Overall Sentiment
Watches of Switzerland Group	Neutral
Dr. Martens	Neutral

Watches of Switzerland Group has a beta of 1.863, indicating that its stock price is 86% more volatile than the broader market. Comparatively, Dr. Martens has a beta of 0.262, indicating that its stock price is 74% less volatile than the broader market.

Watches of Switzerland Group presently has a consensus target price of GBX 696.67, indicating a potential upside of 7.51%. Dr. Martens has a consensus target price of GBX 105, indicating a potential upside of 63.29%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Martens is more favorable than Watches of Switzerland Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Watches of Switzerland Group	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Dr. Martens	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Watches of Switzerland Group has a net margin of 5.42% compared to Dr. Martens' net margin of 3.11%. Watches of Switzerland Group's return on equity of 16.31% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Watches of Switzerland Group	5.42%	16.31%	7.41%
Dr. Martens	3.11%	6.89%	8.12%

Dr. Martens has lower revenue, but higher earnings than Watches of Switzerland Group. Watches of Switzerland Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Watches of Switzerland Group	£1.83B	0.82	£60.02M	£42.60	15.21
Dr. Martens	£764.90M	0.80	£68.97M	£2.40	26.79

Summary

Watches of Switzerland Group beats Dr. Martens on 9 of the 15 factors compared between the two stocks.

How does Dr. Martens compare to Coats Group?

Dr. Martens (LON:DOCS) and Coats Group (LON:COA) are both small-cap consumer discretionary companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 4.0%. Coats Group pays an annual dividend of GBX 3.28 per share and has a dividend yield of 4.3%. Dr. Martens pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Coats Group pays out 60.9% of its earnings in the form of a dividend. Coats Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Coats Group has a net margin of 6.60% compared to Dr. Martens' net margin of 3.11%. Coats Group's return on equity of 14.43% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Coats Group	6.60%	14.43%	8.48%

32.2% of Dr. Martens shares are held by institutional investors. Comparatively, 64.2% of Coats Group shares are held by institutional investors. 2.9% of Dr. Martens shares are held by company insiders. Comparatively, 3.2% of Coats Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dr. Martens has a beta of 0.262, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Coats Group has a beta of 1.259, suggesting that its stock price is 26% more volatile than the broader market.

Coats Group has higher revenue and earnings than Dr. Martens. Coats Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.80	£68.97M	£2.40	26.79
Coats Group	£1.60B	0.92	£75.12M	£5.39	14.30

In the previous week, Coats Group had 2 more articles in the media than Dr. Martens. MarketBeat recorded 2 mentions for Coats Group and 0 mentions for Dr. Martens. Dr. Martens' average media sentiment score of 0.00 equaled Coats Group'saverage media sentiment score.

Company	Overall Sentiment
Dr. Martens	Neutral
Coats Group	Neutral

Dr. Martens currently has a consensus target price of GBX 105, indicating a potential upside of 63.29%. Coats Group has a consensus target price of GBX 121.20, indicating a potential upside of 57.20%. Given Dr. Martens' higher probable upside, analysts plainly believe Dr. Martens is more favorable than Coats Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Coats Group	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Coats Group beats Dr. Martens on 15 of the 17 factors compared between the two stocks.

How does Dr. Martens compare to Mulberry Group?

Dr. Martens (LON:DOCS) and Mulberry Group (LON:MUL) are both small-cap consumer discretionary companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

32.2% of Dr. Martens shares are owned by institutional investors. Comparatively, 0.5% of Mulberry Group shares are owned by institutional investors. 2.9% of Dr. Martens shares are owned by company insiders. Comparatively, 1.4% of Mulberry Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dr. Martens has a net margin of 3.11% compared to Mulberry Group's net margin of -6.72%. Mulberry Group's return on equity of 78.71% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Mulberry Group	-6.72%	78.71%	-8.70%

Dr. Martens has a beta of 0.262, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Mulberry Group has a beta of 0.685, suggesting that its share price is 32% less volatile than the broader market.

Dr. Martens currently has a consensus target price of GBX 105, suggesting a potential upside of 63.29%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Martens is more favorable than Mulberry Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Mulberry Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Mulberry Group had 1 more articles in the media than Dr. Martens. MarketBeat recorded 1 mentions for Mulberry Group and 0 mentions for Dr. Martens. Dr. Martens' average media sentiment score of 0.00 equaled Mulberry Group'saverage media sentiment score.

Company	Overall Sentiment
Dr. Martens	Neutral
Mulberry Group	Neutral

Dr. Martens has higher revenue and earnings than Mulberry Group. Mulberry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.80	£68.97M	£2.40	26.79
Mulberry Group	£125.47M	1.52	-£39.32M	-£13.00	N/A

Summary

Dr. Martens beats Mulberry Group on 11 of the 15 factors compared between the two stocks.

How does Dr. Martens compare to Pittards?

Dr. Martens (LON:DOCS) and Pittards (LON:PTD) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Dr. Martens has a beta of 0.262, indicating that its share price is 74% less volatile than the broader market. Comparatively, Pittards has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

32.2% of Dr. Martens shares are owned by institutional investors. Comparatively, 30.0% of Pittards shares are owned by institutional investors. 2.9% of Dr. Martens shares are owned by insiders. Comparatively, 68.6% of Pittards shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dr. Martens has higher revenue and earnings than Pittards. Pittards is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.80	£68.97M	£2.40	26.79
Pittards	£20.37M	0.00	N/A	£0.03	N/A

In the previous week, Dr. Martens' average media sentiment score of 0.00 equaled Pittards'average media sentiment score.

Company	Overall Sentiment
Dr. Martens	Neutral
Pittards	Neutral

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 4.0%. Pittards pays an annual dividend of GBX 1 per share. Dr. Martens pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pittards pays out 3,333.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.

Dr. Martens has a net margin of 3.11% compared to Pittards' net margin of 1.97%. Dr. Martens' return on equity of 6.89% beat Pittards' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Pittards	1.97%	3.08%	2.32%

Dr. Martens presently has a consensus target price of GBX 105, suggesting a potential upside of 63.29%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Martens is more favorable than Pittards.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pittards	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Dr. Martens beats Pittards on 11 of the 14 factors compared between the two stocks.

How does Dr. Martens compare to Naibu Global International?

Dr. Martens (LON:DOCS) and Naibu Global International (LON:NBU) are both consumer discretionary companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Dr. Martens has higher revenue and earnings than Naibu Global International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.80	£68.97M	£2.40	26.79
Naibu Global International	N/A	N/A	N/A	N/A	N/A

In the previous week, Dr. Martens' average media sentiment score of 0.00 equaled Naibu Global International'saverage media sentiment score.

Company	Overall Sentiment
Dr. Martens	Neutral
Naibu Global International	Neutral

32.2% of Dr. Martens shares are owned by institutional investors. 2.9% of Dr. Martens shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dr. Martens presently has a consensus price target of GBX 105, suggesting a potential upside of 63.29%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts plainly believe Dr. Martens is more favorable than Naibu Global International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Naibu Global International	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dr. Martens has a net margin of 3.11% compared to Naibu Global International's net margin of 0.00%. Dr. Martens' return on equity of 6.89% beat Naibu Global International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Naibu Global International	N/A	N/A	N/A

Summary

Dr. Martens beats Naibu Global International on 9 of the 9 factors compared between the two stocks.

Get Dr. Martens News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOCS vs. The Competition

Export

Metric	Dr. Martens	Textiles, Apparel & Luxury Goods Industry	Consumer Discretionary Sector	LON Exchange
Market Cap	£615.49M	£10.28B	£12.71B	£2.51B
Dividend Yield	3.58%	2.83%	58.24%	6.23%
P/E Ratio	26.79	22.62	45.78	366.83
Price / Sales	0.80	9.34	93.57	83,599.68
Price / Cash	14.29	188.19	28.56	27.89
Price / Book	1.70	3.63	4.08	6.33
Net Income	£68.97M	£462.82M	£445.67M	£5.89B
7 Day Performance	-10.69%	-3.27%	-2.31%	-0.69%
1 Month Performance	-27.09%	-8.04%	-3.96%	0.18%
1 Year Performance	-30.10%	6.00%	-6.12%	20.03%

Dr. Martens Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOCS Dr. Martens	3.1974 of 5 stars	GBX 64.30 -1.4%	GBX 105 +63.3%	-29.0%	£615.49M	£764.90M	26.79	890	Gap Up
WOSG Watches of Switzerland Group	0.8637 of 5 stars	GBX 682 -1.2%	GBX 596.67 -12.5%	+79.6%	£1.58B	£1.83B	16.01	2,553
COA Coats Group	3.7013 of 5 stars	GBX 78.05 -1.1%	GBX 121.20 +55.3%	-6.3%	£1.49B	£1.60B	14.48	15,539	News Coverage Analyst Forecast Gap Down
MUL Mulberry Group	N/A	GBX 256.24 +0.5%	N/A	+197.0%	£179.78M	£125.47M	19.71	1,300
PTD Pittards	N/A	N/A	N/A	N/A	£772K	£20.37M	179.17	1,095

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DOCS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Martens (DOCS) Competitors

DOCS vs. WOSG, COA, MUL, PTD, and NBU

How does Dr. Martens compare to Watches of Switzerland Group?

Summary

How does Dr. Martens compare to Coats Group?

Summary

How does Dr. Martens compare to Mulberry Group?

Summary

How does Dr. Martens compare to Pittards?

Summary

How does Dr. Martens compare to Naibu Global International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS vs. The Competition

Dr. Martens Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Martens (DOCS) Competitors

DOCS vs. WOSG, COA, MUL, PTD, and NBU

How does Dr. Martens compare to Watches of Switzerland Group?

Do institutionals & insiders believe in WOSG or DOCS?

Does the media refer more to WOSG or DOCS?

Which has more risk & volatility, WOSG or DOCS?

Do analysts rate WOSG or DOCS?

Is WOSG or DOCS more profitable?

Which has stronger valuation and earnings, WOSG or DOCS?

Summary

How does Dr. Martens compare to Coats Group?

Is DOCS or COA a better dividend stock?

Is DOCS or COA more profitable?

Do insiders & institutionals believe in DOCS or COA?

Which has more volatility and risk, DOCS or COA?

Which has better earnings and valuation, DOCS or COA?

Does the media favor DOCS or COA?

Do analysts rate DOCS or COA?

Summary

How does Dr. Martens compare to Mulberry Group?

Do insiders and institutionals hold more shares of DOCS or MUL?

Is DOCS or MUL more profitable?

Which has more volatility & risk, DOCS or MUL?

Do analysts prefer DOCS or MUL?

Does the media favor DOCS or MUL?

Which has preferable earnings & valuation, DOCS or MUL?

Summary

How does Dr. Martens compare to Pittards?

Which has more volatility & risk, DOCS or PTD?

Do insiders & institutionals have more ownership in DOCS or PTD?

Which has preferable valuation & earnings, DOCS or PTD?

Does the media favor DOCS or PTD?

Is DOCS or PTD a better dividend stock?

Is DOCS or PTD more profitable?

Do analysts prefer DOCS or PTD?

Summary

How does Dr. Martens compare to Naibu Global International?

Which has better valuation and earnings, DOCS or NBU?

Does the media refer more to DOCS or NBU?

Do institutionals & insiders hold more shares of DOCS or NBU?

Do analysts prefer DOCS or NBU?

Is DOCS or NBU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS vs. The Competition

Dr. Martens Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools